Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Colgate management

This article was originally published in The Tan Sheet

Executive Summary

Chief Operating Officer Ian Cook will succeed President William Shanahan upon his retirement Sept. 30, the firm reports. Colgate announced the appointment earlier this year, signaling Cook was a likely contender to replace CEO Reuben Mark, who said in 2004 he planned to step down in two to four years ("The Tan Sheet" Feb. 9, 2004, p. 7). Cook will retain his COO title. Separately, Colgate released its second quarter results July 27. Oral care, personal care and home care sales grew 11% to $2.46 bil., and operating profit in the segment was up 4% to $527.4 mil. Net sales for the quarter grew 10.5% to $2.84 bil., but net income including restructuring charges fell 8% to $342.9 mil...

You may also be interested in...

Colgate President Cook Slated For CEO Post After Mark’s 2007 Retirement

Colgate-Palmolive President and COO Ian Cook will take over the chief executive position after current Chairman and CEO Reuben Mark retires in 2007, according to Mark

Zydus Cadila Testing Three-Dose COVID-19 Vaccine

Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.

Six Questions For Sun Pharma MD Shanghvi

Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts